Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALGeneric

NYSTATIN

NYSTATIN

Standard Dose
100%
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview NYSTATIN is listed in Drugs@FDA under application 062613 (ANDA).

Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;ORAL - 100% Sponsor PADDOCK LLC Submission history Latest submission status date: 2002-03-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview NYSTATIN is listed in Drugs@FDA under application 062613 (ANDA). Marketing status: Discontinued Active ingredient NYSTATIN Form and strength POWDER;ORAL - 100% Sponsor PADDOCK LLC Submission history Latest submission status date: 2002-03-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.